LGM Pharma, a leading provider of customized API sourcing, contract analytical testing, and CDMO services for the entire pharmaceutical lifecycle, today announced the second phase of its CDMO growth strategy, committing an additional $9 million to facilities in Rosenberg, Texas, and Colorado Springs, Colorado. This investment follows the company’s previously announced $6 million expansion in Rosenberg in 2025 to increase commercial capacity, expand research and development capabilities, and support continued demand for U.S.-based pharmaceutical manufacturing.
Texas facility enhancements include a $4 million investment to expand its commercial-scale suppository manufacturing suite in response to increased customer and market demand, including growth in women’s health products. The upgrade also expands research and development capabilities to support formulation and scale-up of suppositories, solutions, suspensions, and semi-solids. The Rosenberg site will remain fully operational during construction, with upgrades already underway.
In Colorado Springs, LGM Pharma will invest $5 million to expand its commercial manufacturing capacity for niche, high-value oral solid dosage (OSD) products, including orally disintegrating tablets (ODT). This facility has served as the company’s center for OSD development. The expansion, scheduled to be completed this year, will support growing demand for domestic manufacturing. The global OSD CDMO market in 2024 was valued at $43.65 billion, with North America accounting for approximately 40.5% of global OSD pharmaceutical manufacturing activity.
These multi-location investments, totaling $15 million, reflect our continued commitment to strengthening the U.S. pharmaceutical supply chain.. Today’s pharmaceutical companies need partners who are resilient and integrated across the product lifecycle. Build a balanced end-to-end model by strengthening domestic drug manufacturing downstream in the supply chain close to end markets and leveraging global API sourcing capabilities upstream. This gives customers greater control and visibility as they move their products from development to commercialization. ”
Mr. Prasad Raje, Chief Executive Officer, LGM Pharma
At the early drug substance stage of the supply chain, LGM Pharma supports 505(b)(2), NDA, and ANDA programs through a global network of over 220 pre-qualified API manufacturers. The company provides integrated support throughout the drug lifecycle by combining global drug substance sourcing with expanded final dose development and manufacturing in the United States.
LGM Pharma Chief Commercial Officer Hamilton Lennox said the company’s previous Rosenberg upgrades from the first phase of the expansion have been completed, including the introduction of an enhanced track-and-trace serialization system and increased production. “We are executing the next phase of expansion with both facilities fully operational.” Lennox said. “Our team is experienced in managing complex upgrades without sacrificing quality or disrupting customer supply, and this continues to be our top operational priority. Rather than overextend in a single phase, we are implementing these enhancements in phases to expand functionality and capacity while ensuring operational continuity. This approach allows us to strengthen our infrastructure, support customer growth, and scale in response to market demand.”
Companies developing 505(b)(2), NDA, or ANDA products and those with commercial brand or generic portfolios are encouraged to explore LGM Pharma’s API sourcing and expanded drug manufacturing capabilities by visiting LGMPharma.com or meeting with company executives at DCAT Week, March 23-26, 2026 in New York City.
